HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop infectious disease product candidates intended to support functional cures for chronic Hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.
IPO Year: 2019
Exchange: NASDAQ
Website: hookipapharma.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
12/2/2022 | Neutral → Underperform | BofA Securities | |
2/17/2022 | $15.00 → $8.00 | Buy | HC Wainwright & Co. |
2/16/2022 | $3.00 → $4.00 | Outperform | SVB Leerink |
11/12/2021 | $6.00 | Overweight → Equal-Weight | Morgan Stanley |
11/11/2021 | $21.00 → $15.00 | Buy | HC Wainwright & Co. |
11/10/2021 | $28.00 → $10.00 | Outperform | SVB Leerink |
11/10/2021 | $24.00 → $17.00 | Outperform | RBC Capital |
11/10/2021 | $25.00 → $11.00 | Market Outperform | JMP Securities |
8/18/2021 | $19.00 → $18.00 | Overweight | Morgan Stanley |
4 - HOOKIPA Pharma Inc. (0001760542) (Issuer)
4 - HOOKIPA Pharma Inc. (0001760542) (Issuer)
4 - HOOKIPA Pharma Inc. (0001760542) (Issuer)
3 - HOOKIPA Pharma Inc. (0001760542) (Issuer)
4 - HOOKIPA Pharma Inc. (0001760542) (Issuer)
4 - HOOKIPA Pharma Inc. (0001760542) (Issuer)
4 - HOOKIPA Pharma Inc. (0001760542) (Issuer)
4 - HOOKIPA Pharma Inc. (0001760542) (Issuer)
4 - HOOKIPA Pharma Inc. (0001760542) (Issuer)
4 - HOOKIPA Pharma Inc. (0001760542) (Issuer)
Director Dr. Malte Peters named Chief Executive Officer and Director Terry Coelho named Executive Vice President and Chief Financial OfficerCompany is conducting a review of its business operations and strategy to determine best path to create shareholder value and realize the full potential of HB-200Sean Cassidy appointed to the Board of Directors NEW YORK and VIENNA, July 22, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK) ("HOOKIPA" or the "Company"), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Directors Dr. Malte Peters as Chief Executive Officer and Terry Coelho as Executive Vice Presi
HOOKIPA Pharma Inc (NASDAQ:HOOK) shares are trading lower by 10.9% to $0.50 during Monday’s session after the company announced a 1-for-10 reverse stock split, effective at 5:00 p.m. ET on July 9. The stock will start trading on a split-adjusted basis on July 10. This move aims to meet Nasdaq’s minimum bid price requirement for continued listing. Post-split, every 10 shares will be consolidated into one share, maintaining the same par value per share. Fractional shares will not be issued; instead, stockholders will receive a cash payment for any fractional shares. Read Also: French Luxury Stocks Fall As Tax Concerns Rise After Left-Wing Election Upset How To Buy HOOK Stock Besid
HOOKIPA Pharma Inc. (NASDAQ:HOOK, ", HOOKIPA", ))))), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that a 1-for-10 reverse stock split of its outstanding shares of common stock will be effective as of 5:00 p.m. Eastern Time on July 9, 2024. The Company's common stock will begin trading on a reverse stock split-adjusted basis at the opening of the market on July 10, 2024. Following the reverse stock split, the Company's common stock will continue to trade on the Nasdaq Capital Market under the symbol "HOOK" with the new CUSIP number 43906K209. The reverse stock split is part of the Company's plan to regain compliance w
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Keybanc raised the price target for HealthEquity, Inc. (NASDAQ:HQY) from $95 to $100. Keybanc analyst Scott Schoenhaus maintained an Overweight rating. HealthEquity shares gained 2.7% to close at $83.40 on Tuesday. See how other analysts view this stock. HC Wainwright & Co. boosted the price target for HOOKIPA Pharma Inc. (NASDAQ:HOOK) from $5 to $6. HC Wainwright & Co. analyst Arthur He maintained a Buy rating. HOOKIPA Pharma shares fell 8.1% to close at $0.7990 on Tuesday. See how other analysts
HC Wainwright & Co. analyst Arthur He maintains HOOKIPA Pharma (NASDAQ:HOOK) with a Buy and raises the price target from $5 to $6.
Encouraging clinical activity with observed deepening of responses in 35 evaluable first line head and neck patients treated with HB-200 plus pembrolizumabIn a subset of 17 evaluable patients with PD-L1 combined positive score (CPS) of 20 or higher, the Company's selected registrational pivotal trial population, data showed confirmed ORR of 53%, CR rate of 18%, and DCR of 82%Preliminary progression-free survival (PFS) was 16.3 months and preliminary overall survival (OS) rate was 88% at 9 months for the CPS 20 or higher subgroup, comparing favorably to current standard of careCompany will host a conference call at 4:15 p.m. ET today
Gainers Innovative Eyewear (NASDAQ:LUCY) shares moved upwards by 421.5% to $0.97 during Monday's regular session. The company's market cap stands at $16.9 million. OneMedNet (NASDAQ:ONMD) shares moved upwards by 55.78% to $2.29. The company's market cap stands at $54.6 million. Qilian Intl Hldg Gr (NASDAQ:QLI) shares moved upwards by 37.59% to $0.91. The company's market cap stands at $32.4 million. Onconetix (NASDAQ:ONCO) shares moved upwards by 29.7% to $0.18. The market value of their outstanding shares is at $4.0 million. TransCode Therapeutics (NASDAQ:RNAZ) shares moved upwards by 28.77% to $1.79. The company's market cap stands at $11.8 million. MultiPlan (NYSE:MPLN) stock rose 2
8-K - HOOKIPA Pharma Inc. (0001760542) (Filer)
424B5 - HOOKIPA Pharma Inc. (0001760542) (Filer)
10-Q - HOOKIPA Pharma Inc. (0001760542) (Filer)
8-K - HOOKIPA Pharma Inc. (0001760542) (Filer)
8-K - HOOKIPA Pharma Inc. (0001760542) (Filer)
8-K - HOOKIPA Pharma Inc. (0001760542) (Filer)
8-K - HOOKIPA Pharma Inc. (0001760542) (Filer)
8-K - HOOKIPA Pharma Inc. (0001760542) (Filer)
8-K - HOOKIPA Pharma Inc. (0001760542) (Filer)
10-Q - HOOKIPA Pharma Inc. (0001760542) (Filer)
BofA Securities downgraded HOOKIPA Pharma from Neutral to Underperform
HC Wainwright & Co. reiterated coverage of HOOKIPA Pharma with a rating of Buy and set a new price target of $8.00 from $15.00 previously
SVB Leerink reiterated coverage of HOOKIPA Pharma with a rating of Outperform and set a new price target of $4.00 from $3.00 previously
Morgan Stanley downgraded HOOKIPA Pharma from Overweight to Equal-Weight and set a new price target of $6.00
HC Wainwright & Co. reiterated coverage of HOOKIPA Pharma with a rating of Buy and set a new price target of $15.00 from $21.00 previously
SVB Leerink reiterated coverage of HOOKIPA Pharma with a rating of Outperform and set a new price target of $10.00 from $28.00 previously
RBC Capital reiterated coverage of HOOKIPA Pharma with a rating of Outperform and set a new price target of $17.00 from $24.00 previously
JMP Securities reiterated coverage of HOOKIPA Pharma with a rating of Market Outperform and set a new price target of $11.00 from $25.00 previously
Morgan Stanley reiterated coverage of HOOKIPA Pharma with a rating of Overweight and set a new price target of $18.00 from $19.00 previously
HC Wainwright & Co. reiterated coverage of HOOKIPA Pharma with a rating of Buy and set a new price target of $21.00 from $16.00 previously
SC 13G/A - HOOKIPA Pharma Inc. (0001760542) (Subject)
SC 13G - HOOKIPA Pharma Inc. (0001760542) (Subject)
SC 13D - HOOKIPA Pharma Inc. (0001760542) (Subject)
SC 13G - HOOKIPA Pharma Inc. (0001760542) (Subject)
SC 13G/A - HOOKIPA Pharma Inc. (0001760542) (Subject)
SC 13G/A - HOOKIPA Pharma Inc. (0001760542) (Subject)
SC 13G/A - HOOKIPA Pharma Inc. (0001760542) (Subject)
SC 13G/A - HOOKIPA Pharma Inc. (0001760542) (Subject)
SC 13G/A - HOOKIPA Pharma Inc. (0001760542) (Subject)
SC 13G - HOOKIPA Pharma Inc. (0001760542) (Subject)
NEW YORK and VIENNA, Aug. 30, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK) ("HOOKIPA" or the "Company"), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Director Julie O'Neill as Non-Executive Chair of the Company's Board of Directors. She succeeds Jan van de Winkel, who has decided to step down from the Board effective August 30, 2024, due to increasing time commitments from his executive position as Chief Executive Officer of Genmab A/S. The Company also announced that Tim Reilly has chosen to step down from the Board, also effective August 30th, to be able to dedicate more time to his o
NEW YORK and VIENNA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, "HOOKIPA", the "Company"))), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that members of the management team will participate in the H.C. Wainwright 26th Annual Global Investment Conference, taking place from September 9th-11th, 2024 in New York. Dr. Malte Peters, Hookipa's Chief Executive Officer, and Terry Coelho, Executive Vice President & Chief Financial Officer will be hosting one-on-one meetings with investors during the conference. In addition, Dr. Peters will participate in a Fireside Chat on Monday, September 9, 2024 at
New Leadership Appointments; Positive Clinical and Regulatory Reports for the Lead Product Candidate, HB-200 (eseba-vec); On track to initiate the Phase 2/3 "AVALON-1" study with eseba-vec in Q4 2024 ASCO 2024 Presentation: Reported best-in-class Phase 2 data for first-line HPV16+ head and neck cancer patients treated with eseba-vec (formerly HB-200) in combination with pembrolizumab during oral presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual MeetingRegulatory Progress: Announced alignment with U.S. Food and Drug Administration (FDA) for the AVALON-1 Phase 2/3 pivotal trial design and protocol for eseba-vec, in combination with pembrolizumab for the first-li
Director Dr. Malte Peters named Chief Executive Officer and Director Terry Coelho named Executive Vice President and Chief Financial OfficerCompany is conducting a review of its business operations and strategy to determine best path to create shareholder value and realize the full potential of HB-200Sean Cassidy appointed to the Board of Directors NEW YORK and VIENNA, July 22, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK) ("HOOKIPA" or the "Company"), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Directors Dr. Malte Peters as Chief Executive Officer and Terry Coelho as Executive Vice Pr
NEW YORK and VIENNA, July 08, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, "HOOKIPA"))), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that a 1-for-10 reverse stock split of its outstanding shares of common stock will be effective as of 5:00 p.m. Eastern Time on July 9, 2024. The Company's common stock will begin trading on a reverse stock split-adjusted basis at the opening of the market on July 10, 2024. Following the reverse stock split, the Company's common stock will continue to trade on the Nasdaq Capital Market under the symbol "HOOK" with the new CUSIP number 43906K209. The reverse stock split is
Novel arenaviral therapeutic vaccine, developed in collaboration with Gilead Sciences, Inc. (Gilead), to be evaluated as a potential component of a curative regimen for human immunodeficiency virus (HIV)HOOKIPA achieves a $5 million non-dilutive milestone payment under its collaboration and license agreement with Gilead Under the collaboration agreement, HOOKIPA is responsible for advancing the HIV program through the completion of a Phase 1b clinical trial NEW YORK and VIENNA, July 01, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, HOOKIPA))), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the first
Encouraging clinical activity with observed deepening of responses in 35 evaluable first line head and neck patients treated with HB-200 plus pembrolizumabIn a subset of 17 evaluable patients with PD-L1 combined positive score (CPS) of 20 or higher, the Company's selected registrational pivotal trial population, data showed confirmed ORR of 53%, CR rate of 18%, and DCR of 82%Preliminary progression-free survival (PFS) was 16.3 months and preliminary overall survival (OS) rate was 88% at 9 months for the CPS 20 or higher subgroup, comparing favorably to current standard of careCompany will host a conference call at 4:15 p.m. ET today NEW YORK and VIENNA, June 04, 2024 (GLOBE NEWSWIRE) -- H
Company will present promising preliminary progression-free survival and overall survival data for patients with combined positive score (CPS) ≥20Conference call on Tuesday, June 4, at 4:15 p.m. ET NEW YORK and VIENNA, May 30, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, HOOKIPA or the Company))), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that members of HOOKIPA's Executive Team will host an investor call on June 4, 2024, at 4:15 p.m. ET. Complete details and registration information are included below. The call will detail the Company's Phase 2 clinical data of HB-200 in combination with pembrolizuma
HOOKIPA to present an oral abstract at the American Society for Clinical Oncology (ASCO) 2024 Annual Meeting on June 4Updated data of HB-200 plus pembrolizumab demonstrate a favorable safety profile and promising clinical activity In a subset of patients with PD-L1 combined positive score (CPS) of 20 or higher, data showed confirmed objective response rate (ORR) of 53%, complete response (CR) rate of 18%, and disease control rate (DCR) of 82% Company will also present promising preliminary progression-free survival and overall survival data for patients with CPS ≥20 on June 4 NEW YORK and VIENNA, May 23, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA'))), a company
Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or metastatic OPSCC aligns with U.S. Food and Drug Administration (FDA) feedbackHB-200 program received Priority Medicines (PRIME) designation from the European Medicines Agency (EMA)Received FDA clearance for Investigational New Drug (IND) application for HB-700 for the treatment of KRAS mutated cancers NEW YORK and VIENNA, May 09, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA'))), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reported financial results a
NEW YORK and VIENNA, Aug. 30, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK) ("HOOKIPA" or the "Company"), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Director Julie O'Neill as Non-Executive Chair of the Company's Board of Directors. She succeeds Jan van de Winkel, who has decided to step down from the Board effective August 30, 2024, due to increasing time commitments from his executive position as Chief Executive Officer of Genmab A/S. The Company also announced that Tim Reilly has chosen to step down from the Board, also effective August 30th, to be able to dedicate more time to his o
New Leadership Appointments; Positive Clinical and Regulatory Reports for the Lead Product Candidate, HB-200 (eseba-vec); On track to initiate the Phase 2/3 "AVALON-1" study with eseba-vec in Q4 2024 ASCO 2024 Presentation: Reported best-in-class Phase 2 data for first-line HPV16+ head and neck cancer patients treated with eseba-vec (formerly HB-200) in combination with pembrolizumab during oral presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual MeetingRegulatory Progress: Announced alignment with U.S. Food and Drug Administration (FDA) for the AVALON-1 Phase 2/3 pivotal trial design and protocol for eseba-vec, in combination with pembrolizumab for the first-li
Director Dr. Malte Peters named Chief Executive Officer and Director Terry Coelho named Executive Vice President and Chief Financial OfficerCompany is conducting a review of its business operations and strategy to determine best path to create shareholder value and realize the full potential of HB-200Sean Cassidy appointed to the Board of Directors NEW YORK and VIENNA, July 22, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK) ("HOOKIPA" or the "Company"), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Directors Dr. Malte Peters as Chief Executive Officer and Terry Coelho as Executive Vice Pr
NEW YORK and VIENNA, Austria, Jan. 16, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA'))), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Mark Winderlich, PhD, as Chief Development Officer, effective April 1, 2024 (‘effective date'). Dr. Winderlich has rich experience leading multiple candidates through the drug development process to product approval in the United States and in Europe. "We are pleased to bring our search for a capable clinical development leader to such a swift, successful resolution and welcome Mark to the team," said Joern Aldag, Chief Executive Officer at HOOK
HOOKIPA on track to report Phase 2 data on HB-200 for head and neck cancer in combination with pembrolizumab in 2Q 2023Phase 1 clinical trials initiated for two programs (HB-300 for advanced prostate cancer and Gilead-partnered HB-400 for chronic hepatitis B)HB-700 for KRAS-mutated cancers achieved $10 million milestone payment in Roche collaboration NEW YORK and VIENNA, May 11, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA'))), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reported financial results and business highlights for the first quarter of 2023. "We are happy to report continued progress across ou
NEW YORK and VIENNA, March 13, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA'))), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced today that Terry Coelho will join its Board of Directors, Audit Committee and Compensation Committee, effective April 3, 2023. "Terry is an immensely valuable addition to our Board given her experience in business strategy, broad financial transactions and business development, and we are thrilled to welcome her to the team," said Joern Aldag, Chief Executive Officer at HOOKIPA. "Terry has worked with companies large and small and navigated fast-paced, complex business envi
NEW YORK and VIENNA, Austria, Dec. 15, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA'))), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced today the promotion of Katia Schlienger, M.D., Ph.D., to Chief Medical Officer and the appointment of Malte Peters, M.D., to its Board of Directors, both effective January 1, 2023. "Katia has had a major impact on HOOKIPA's clinical development strategy and execution in immuno-oncology therapeutics and vaccines since she joined the Company in 2021. She will be leading the progression of our clinical programs to the next level, specifically our own programs in head and n
NEW YORK and VIENNA, Austria, April 20, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA'))), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Tim Reilly, Ph.D. to its Board of Directors, effective immediately. "We're pleased to have Tim join our Board as we advance our oncology pipeline of novel arenaviral immunotherapeutics in and towards the clinic," said Joern Aldag, Chief Executive Officer at HOOKIPA. "Tim's experience in product development, especially driving early clinical development that supports eventual marketed products, is enormously relevant to our current focus. We wil
Proprietary arenavirus immunotherapeutics platform demonstrated promising clinical activity with interim data from lead oncology and infectious disease candidatesFollow-on offering strengthened cash basis with $143 million available at year-end to support progression of Human Papillomavirus 16-positive (HPV16+) cancer and Cytomegalovirus (CMV) programs and pipeline expansion HOOKIPA on track to report additional clinical data on efficacy and T cell response in 2021 for HB-201 and HB-202 NEW YORK and VIENNA, Austria, March 18, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus p
Encouraging clinical activity with observed deepening of responses in 35 evaluable first line head and neck patients treated with HB-200 plus pembrolizumabIn a subset of 17 evaluable patients with PD-L1 combined positive score (CPS) of 20 or higher, the Company's selected registrational pivotal trial population, data showed confirmed ORR of 53%, CR rate of 18%, and DCR of 82%Preliminary progression-free survival (PFS) was 16.3 months and preliminary overall survival (OS) rate was 88% at 9 months for the CPS 20 or higher subgroup, comparing favorably to current standard of careCompany will host a conference call at 4:15 p.m. ET today NEW YORK and VIENNA, June 04, 2024 (GLOBE NEWSWIRE) -- H
Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or metastatic OPSCC aligned with FDA feedback HB-200 accepted for oral abstract presentation at ASCO 2024 Annual Meeting with data from approximately 40 patients treated with HB-200 in combination with pembrolizumab Two additional abstracts for HB-200 and HB-700 accepted for the ASCO 2024 Annual Meeting Company to host investor call at 8:00 a.m. ET on Thursday, April 25, 2024, to highlight path to potential registration; participant details below NEW YORK and VIENNA, Austria, April 25, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDA
NEW YORK and VIENNA, Austria, Nov. 02, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA'))), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release its third quarter 2023 financial results and business highlights on November 9, 2023. The company will not be conducting a conference call in conjunction with this financial release. About HOOKIPAHOOKIPA Pharma Inc. (NASDAQ:HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which are designed to mobilize and amplify targeted T cells and thereby fight o
NEW YORK and VIENNA, Austria, Aug. 03, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA'))), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release its second quarter 2023 financial results and business highlights on August 10, 2023. The company will not be conducting a conference call in conjunction with this financial release. About HOOKIPAHOOKIPA Pharma Inc. (NASDAQ:HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which are designed to mobilize and amplify targeted T cells and thereby fight o
NEW YORK and VIENNA, Austria, May 04, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA'))), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release its first quarter 2023 financial results and business highlights on May 11, 2023. The company will not be conducting a conference call in conjunction with this financial release. About HOOKIPAHOOKIPA Pharma Inc. (NASDAQ:HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which are designed to mobilize and amplify targeted T cells and thereby fight or pre
NEW YORK and VIENNA, March 08, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA'))), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release fourth quarter and full year 2022 financial results before the market opens on Wednesday, March 15, 2023. The Company will host a live conference call and webcast at 8:30 AM ET to discuss its financial results and provide a corporate update. Conference Call & Webcast: Date: March 15, 2023Time: 8:30 AM ETUSA Dial In: +1-800-715-9871UK Dial In: 0800-260-6466Austria Dial In: +43 800-070-441Conference ID: 7669853Webcast: Link The webcast and
NEW YORK and VIENNA, Austria, Nov. 07, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA'))), a company developing a new class of immunotherapies based on its proprietary arenavirus platform, today announced it will release its third quarter 2022 financial results and Company update before the market opens on Monday, November 14, 2022. The company will not be conducting a conference call in conjunction with this earnings release. About HOOKIPAHOOKIPA Pharma Inc. (NASDAQ:HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which are designed to mobilize and amplify targeted T ce
NEW YORK and VIENNA, Austria, Aug. 04, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA'))), a company developing a new class of immunotherapies based on its proprietary arenavirus platform, today announced that it will release its second quarter 2022 financial results and Company update before the market open on Thursday, August 11, 2022. The Company will not be conducting a conference call in conjunction with this earnings release.About HOOKIPA HOOKIPA Pharma Inc. (NASDAQ:HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which are designed to mobilize and amplify targeted T c
NEW YORK and VIENNA, Austria, May 09, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA'))), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release first quarter 2022 financial results before the market open on Monday, May 16, 2022. The Company will not be conducting a conference call in conjunction with this earnings release.About HOOKIPA HOOKIPA Pharma Inc. (NASDAQ:HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, that are designed to mobilize and amplify targeted T cells and thereby fight or pr
Lead oncology candidate HB-200 demonstrated high antigen-specific T cell responses and encouraging anti-tumor activity in heavily pre-treated head and neck cancer patientsHOOKIPA received FDA Fast Track designation and advanced HB-200 to Phase 2 trial in combination with pembrolizumab, with data anticipated in H2 2022HOOKIPA and Gilead agreed to advance partnered HIV program, triggering $54 million commitment from GileadStrong 2021 year-end pro forma cash position of $156.9 million when giving effect to payments received in Q1 2022 from Gilead transaction and proceeds of $75 million public follow-on offering NEW YORK and VIENNA, Austria, March 24, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma I